Background: Thrombocyte volume parameters such as mean thrombocyte volume (MPV) and PDW (thrombocyte distribution volume) are parameters used in evaluation of thrombocyte size which have hemostatic importance. The increased thrombocyte volume is a marker of thrombocyte activation. The thrombocyte activity is important in pathophysiology of diseases with a tendency of thrombosis and inflammation. In adult studies it has been reported that MPV increases in thrombotic diseases such as obesity, diabetes mellitus (DM), atherosclerosis, cerebrovascular diseases.
Objective and hypotheses: The aim of the present study is to evaluate the risk of thrombosis by measurement of MPV and PDW values, in type 1 DM patients with and without the clinical findings of diabetic ketoacidosis (DKA).
Method: The complete blood counts of 20 type 1 DM patients who has admitted with DKA and 26 type 1 DM patients without ketoacidosis and age and gender-matched 30 control cases were investigated at the time of admission, at least 1 week after improvement of clinical findings of ketoacidosis and at least 3 months after the admission and MPV and PDW values were recorded. pH and HCO3 values in blood gas analysis, HbA1c and blood glucose values were also recorded.
Results: MPV and PDW values at the time of admission were found to be higher in cases with DKA when compared with the cases without DKA and also the values were found to be higher in cases without DKA when compared with the control group. A significant negative correlation was found between MPV values and pH and HCO3 values in patients admitted with DKA. In all type 1 DM patients, a decrease was observed in MPV values in parallel to the decrease in HbA1c and blood glucose levels 3 months after the diagnosis.
Conclusion: It has been demonstrated that MPV and PDW values in cases admitted with DKA were higher when compared with the cases without ketoacidosis and the control group, and this increase in MPV values is related with the degree of acidosis and MPV values became normal after initiation of fluid and insulin treatment. The clinical manifestation of DKA is related with fluid-electrolyte loss, tendency to thrombosis and systemic inflammatory process. The measurement of thrombocyte volume parameters in cases with the clinical findings of DKA could be used in the diagnosis and progress of the disease.
Disclosures: NZ-L, ZG, consultant (Novo Nordisk, Spring). MHR, MBO, employees Novo Nordisk. LS, consultant (Ferring, Novo Nordisk, Merck Serono, Pfizer, Sandoz); grants (Merck Serono, Novo Nordisk, Pfizer). TB, boardmember (Novo Nordisk, Sanofi, Eli Lilly, Medtronic, Bayer Health Care); institutional grant/expenses (Abbott, Medtronic, Novo Nordisk, GluSense, Sanofi, Sandoz, Diamyd); speaker bureaux (Eli Lilly, Bayer, Novo Nordisk, Medtronic, Sanofi, Roch); stocks (DreamMed).
01 - 03 Oct 2015
European Society for Paediatric Endocrinology